May. 6 at 10:40 AM
$ELAN Elanco raises FY26 adjusted EPS view to
$1.03-
$1.09 from
$1.00-
$1.06
Consensus
$1.03. Raises FY26 revenue view
$5.01B-
$5.09B from
$4.95B-
$5.02B, consensus
$5B. Raises FY26 adjusted EBITDA view to
$975M-
$1.01B from
$955M-
$985M. "Our strong first quarter results underscore the powerful momentum we are carrying into 2026," said Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health. "This outperformance, driven by both volume and price, gives us the confidence to raise our full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, while continuing to take a prudent, balanced approach in a dynamic macro environment.
We remain disciplined in our execution of Elanco Ascend, which is already delivering meaningful efficiencies and positions us for significant, sustainable margin expansion starting this year. With accelerating free cash flow and an improved net leverage target, Elanco is operating from a position of financial strength to drive long-term shareholder value."
